Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Debt: 2013-2023

Historic Non-Current Debt for Capricor Therapeutics (CAPR) over the last 11 years, with Dec 2023 value amounting to $3.4 million.

  • Capricor Therapeutics' Non-Current Debt changed negligibly% to $3.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.4 million for FY2023, which is negligibly% changed negligibly from last year.
  • As of FY2023, Capricor Therapeutics' Non-Current Debt stood at $3.4 million, which was down 0.00% from $3.4 million recorded in FY2022.
  • Over the past 5 years, Capricor Therapeutics' Non-Current Debt peaked at $3.4 million during FY2019, and registered a low of $3.4 million during FY2019.
  • Its 3-year average for Non-Current Debt is $3.4 million, with a median of $3.4 million in 2023.